
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is supported by powerful incretin franchise momentum, with Zepbound and Mounjaro driving a projected 3Q26 revenue beat and an expected guidance increase of about $2bn, while Mounjaro also continues to gain share ex-US and Zepbound volumes remain strong despite modest pricing pressure. The company’s Bridge program appears manageable, reducing Zepbound revenue by only about $132m, or roughly 2.5% of 3Q sales, while still expanding new starts and reinforcing demand elasticity. Beyond obesity and diabetes, the newly updated Inluriyo label with Verzenio strengthens the oncology pipeline, and management’s above-average sales and EPS growth outlook is backed by 2025-32 CAGR estimates of 13% and 18%, respectively.
Bears say
Eli Lilly is facing weakening fundamentals as Verzenio, Taltz, and Trulicity all missed expectations, with Trulicity TRx down over 20% y/y for the third consecutive quarter and Verzenio still hurt by pricing pressure. The company’s outlook is further clouded by MFN pricing that persists all year, mounting competitive and regulatory pressure on the GLP-1 franchise, and an expected 3Q26 EPS of $6.34 versus $9.74 consensus after a modeled $4.2bn IPR&D charge. Even with commercialization spend rising for Foundayo, the risk profile remains skewed negative because slower obesity growth, margin compression, and pipeline disappointment could materially weaken earnings power.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Eli Lilly (LLY) Forecast
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares